Iterum Therapeutics PLC
NASDAQ:ITRM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/S
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.
Valuation Scenarios
If P/S returns to its 3-Year Average (40.3), the stock would be worth $0.32 (1 919% upside from current price).
| Scenario | P/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 2 | $0.02 |
0%
|
| 3-Year Average | 40.3 | $0.32 |
+1 919%
|
| 5-Year Average | 40.3 | $0.32 |
+1 919%
|
| Industry Average | 8.4 | $0.07 |
+321%
|
| Country Average | 1.9 | $0.01 |
-6%
|
Forward P/S
Today’s price vs future revenue
| Today's Market Cap | Revenue | Forward P/S | ||
|---|---|---|---|---|
|
$1.5m
|
/ |
Oct 2025
$390k
|
= |
|
|
$1.5m
|
/ |
Dec 2025
$816k
|
= |
|
|
$1.5m
|
/ |
Dec 2026
$10.2m
|
= |
|
|
$1.5m
|
/ |
Dec 2027
$60.8m
|
= |
|
|
$1.5m
|
/ |
Dec 2028
$49.7m
|
= |
|
Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | P/S | P/E | ||||
|---|---|---|---|---|---|---|
| IE |
|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
779k USD | 2 | -0 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
867B USD | 13.3 | 42 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.4B USD | 5.8 | 26.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
224.8B GBP | 5.1 | 29.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.8B CHF | 5 | 20 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
283.6B USD | 4.4 | 15.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.5 | 10.7 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.4B USD | 2.4 | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.8B USD | 2.5 | 16.9 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0.8 |
| Median | 1.9 |
| 70th Percentile | 3.2 |
| Max | 3 099.8 |
Other Multiples
Iterum Therapeutics PLC
Glance View
Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous (IV) branded penem available. The company is headquartered in Dublin, Dublin and currently employs 13 full-time employees. The company went IPO on 2018-05-25. The firm is focused on developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens. The firm is developing sulopenem - the oral and intervenous (IV) penem antibiotic demonstrating a potent spectrum of activity against multi-drug resistant gram-negative. The company is a bioavailable, antibiotic covering gram-positive, gram-negative and anaerobic pathogen with in-vitro activity against multidrug-resistant pathogens, including Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia, coli and Klebsiella and pneumonia. The firm also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid, which is known as oral sulopenem.
